The X Annual Conference of CIBER-BBN, held in Sevilla last 28 and 29 of November, dedicated a Session to NANBIOSIS on Monday afternoon, to which attended national and international representatives of industry and academia users of NANBIOSIS, representatives of EATRIS and members of the Scientific and Technical Advisory Committee of NANBIOSIS, as well as the CIBER-BBN and the CCMIJU researchers.
Jaume Veciana, Scientific of NANBIOSIS and Ángela Fernández Curto, Assistant Deputy Director General for Planning of Scientific and Technological Infrastructures of Spanish Goverment presented the Unique Technical Scientific Infrastructure (ICTS) of CIBER-BBN and JUMISC for the production and characterization of biomaterials, nanomaterials and devices until their preclinical validation. Among the biomedical applications that frame the activity of NANBIOSIS are diagnostic, regenerative medicine and drug administration, as well as its next Cascade Characterization Service for the preclinical evaluation of nanomedicines.
The project “PRONANBIOSIS” funded by the Spanish Ministry of Economy and Competitiveness with a “Network of Excellence” to consolidate the unified management model of NANBIOSIS, to boost its internationalization and strategic positioning as well as to promote a complete nanomaterials characterization cascade service, was also presented and some of the” success stories “of the ICTS where explained.
Since its launch in July 2015, NANBIOSIS has received more than 250 access requests, with an average participation of about 50 competitive projects per year and annual revenues for its services of between 1 and 2 million euros. Among its users, there are more than 100 companies, especially pharmaceutical laboratories, and more than 300 research groups. In addition, its 27 units are involved in several national and European projects, such as BERENICE (nanoformulation of the active to combat Chagas disease), DRIVE (development of a device with pancreatic cells for diabetes treatment) and several public- Former INNPACTO (PHYTEC -Development of bioactive coated medical products for bone regeneration- and VITILIGO -Development of a new advanced therapy drug for the treatment of Vitiligo-), several projects Challenges Collaboration, or the Network of Excellence Pronanbiosis for the promotion and Consolidation of the ICTS, among others.
At the Conference, the NANBIOSIS Scientific Advisory Committee convened to discuss the key actions of its next Strategic Plan, such as the new Cascade Characterization Service for the preclinical evaluation of nanomedicines.